PE20161417A1 - Composiciones de glicoproteinas sialiladas y uso de estas - Google Patents

Composiciones de glicoproteinas sialiladas y uso de estas

Info

Publication number
PE20161417A1
PE20161417A1 PE2016001535A PE2016001535A PE20161417A1 PE 20161417 A1 PE20161417 A1 PE 20161417A1 PE 2016001535 A PE2016001535 A PE 2016001535A PE 2016001535 A PE2016001535 A PE 2016001535A PE 20161417 A1 PE20161417 A1 PE 20161417A1
Authority
PE
Peru
Prior art keywords
compositions
mol
refers
treatment
composition
Prior art date
Application number
PE2016001535A
Other languages
English (en)
Inventor
Michael Vellard
Jeff Grubb
Steven Jungles
Gabrielle Morris
Emil D Kakkis
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of PE20161417A1 publication Critical patent/PE20161417A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a una composicion que comprende una glicoproteina recombinante que es una ß- glucuronidasa humana de contenido de sialilacion de al menos 0,7 mol/mol de la glicoproteina recombinante y de un nivel elevado de restos de manosa-6-fosfato (M6P). Tambien se refiere a un metodo de preparacion, tratamiento y administracion. Dicha composicion es util en el tratamiento de trastornos relacionados con deficiencias enzimaticas de almacenamiento lisosomico tal como mucopolisacaridosis tipo 7, entre otros
PE2016001535A 2014-03-05 2015-03-05 Composiciones de glicoproteinas sialiladas y uso de estas PE20161417A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461948421P 2014-03-05 2014-03-05
US201562114313P 2015-02-10 2015-02-10

Publications (1)

Publication Number Publication Date
PE20161417A1 true PE20161417A1 (es) 2017-01-22

Family

ID=54016314

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001535A PE20161417A1 (es) 2014-03-05 2015-03-05 Composiciones de glicoproteinas sialiladas y uso de estas

Country Status (17)

Country Link
US (7) US9457067B2 (es)
EP (1) EP3113781B1 (es)
JP (1) JP6581590B2 (es)
KR (1) KR102150481B1 (es)
CN (1) CN106102749B (es)
AU (1) AU2015227137B2 (es)
BR (1) BR112016019893B1 (es)
CA (1) CA2940318C (es)
ES (1) ES2704923T3 (es)
IL (1) IL247550B (es)
MX (1) MX368972B (es)
MY (1) MY188028A (es)
PE (1) PE20161417A1 (es)
PH (1) PH12016501658A1 (es)
RU (1) RU2689119C2 (es)
TW (1) TWI702049B (es)
WO (1) WO2015134696A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3113781B1 (en) 2014-03-05 2018-11-21 Ultragenyx Pharmaceutical Inc. Sialylated glycoprotein compositions and uses thereof
CN111465683A (zh) 2017-12-13 2020-07-28 3M创新有限公司 抗微生物液化的水可重构培养基
TWI667252B (zh) * 2018-07-13 2019-08-01 中原大學 阿伐-選擇性唾液酸供體及其於製備唾液酸苷的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
AU2003249055B2 (en) * 2002-07-15 2008-06-26 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DK1699821T3 (da) * 2003-12-31 2012-07-16 Merck Patent Gmbh Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
EP1818395A1 (en) * 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
BRPI0716997B8 (pt) * 2006-09-10 2021-05-25 Glycotope Gmbh proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma
CA2680189A1 (en) * 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
WO2011096750A2 (en) * 2010-02-08 2011-08-11 Korea Advanced Institute Of Science And Technology Method for preparing recombinant glycoproteins with high sialic acid content
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101457514B1 (ko) * 2011-11-21 2014-11-03 한국생명공학연구원 우렁쉥이(멍게) 유래의 시알산 전이효소 및 이를 이용한 시알화 복합당질 합성 방법
US10138474B2 (en) * 2012-08-17 2018-11-27 Research Foundation Of The City University Of New York Scavenger receptor uptake for fabry disease enzyme replacement therapy
EP3113781B1 (en) 2014-03-05 2018-11-21 Ultragenyx Pharmaceutical Inc. Sialylated glycoprotein compositions and uses thereof

Also Published As

Publication number Publication date
RU2016138790A (ru) 2018-04-09
TWI702049B (zh) 2020-08-21
US20170326210A1 (en) 2017-11-16
US20150250860A1 (en) 2015-09-10
MX2016011416A (es) 2016-12-02
US20200282028A1 (en) 2020-09-10
EP3113781A4 (en) 2017-08-09
RU2016138790A3 (es) 2018-08-23
MX368972B (es) 2019-10-23
US9457068B2 (en) 2016-10-04
US20220202915A1 (en) 2022-06-30
JP6581590B2 (ja) 2019-09-25
AU2015227137A1 (en) 2016-09-15
CN106102749A (zh) 2016-11-09
US9937243B2 (en) 2018-04-10
KR102150481B1 (ko) 2020-09-02
CN106102749B (zh) 2019-07-12
JP2017508455A (ja) 2017-03-30
US20190054153A1 (en) 2019-02-21
EP3113781B1 (en) 2018-11-21
US20150366951A1 (en) 2015-12-24
US9687532B2 (en) 2017-06-27
WO2015134696A1 (en) 2015-09-11
ES2704923T3 (es) 2019-03-20
CA2940318A1 (en) 2015-09-11
MY188028A (en) 2021-11-10
IL247550B (en) 2020-10-29
IL247550A0 (en) 2016-11-30
US9457067B2 (en) 2016-10-04
PH12016501658A1 (en) 2016-10-03
US20160367646A1 (en) 2016-12-22
TW201615210A (zh) 2016-05-01
EP3113781A1 (en) 2017-01-11
RU2689119C2 (ru) 2019-05-24
AU2015227137B2 (en) 2019-06-06
BR112016019893B1 (pt) 2023-02-14
BR112016019893A2 (pt) 2017-10-24
KR20160127124A (ko) 2016-11-02
CA2940318C (en) 2020-09-22

Similar Documents

Publication Publication Date Title
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
AR069168A1 (es) Variantes de alfa -amilasas con propiedades alteradas
SV2017005416A (es) Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados
BR112015006426A2 (pt) composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, proteína e baixos níveis de eletrólitos
BR112015011244A2 (pt) Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
MX2019003364A (es) Composiciones oftalmicas que comprenden ciclosporina.
AR087745A1 (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
BR112013023757A2 (pt) método para redução de viscosidade no processo de sacarificação
BR112015010283A8 (pt) bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, métodos de produzir uma glicoproteína recombinante e de produzir uma vacina de gliconjugado, célula de e. coli modificada, e, vacina
ECSP12011803A (es) Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
AR102445A1 (es) COMPOSICIONES Y MÉTODOS RELACIONADOS CON b-GLUCOSIDASA
BR112017026181A2 (pt) composições de fibra sem madeira e usos na embalagem de papelão
BR112016019735A2 (pt) fhbp, polipeptídeo, plasmídeo ou outro ácido nucleico, célula hospedeira, vesículas de membrana, e, composição imunogênica
MX2017002469A (es) Composiciones de matrices extracelulares.
AR100329A1 (es) Composición y método para el cuidado oral
MX2018007871A (es) Composiciones para el cuidado personal.
PE20161417A1 (es) Composiciones de glicoproteinas sialiladas y uso de estas
BR112015013125A2 (pt) tratamento de lesões orais usando composições de matrix placentário extracelular
BR112015013071A8 (pt) solução de trombina aquosa, seus métodos para liofilização e composição de trombina sólida
MX2015017555A (es) Metodos y composiciones para aumentar la movilizacion de las celulas madre.
AR092691A1 (es) Composicion farmaceutica que comprende rebamipida
EA201690597A1 (ru) Композиция для применения при лечении кашля
PH12016500708A1 (en) Recombinant glycoproteins and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal